



January 2024

Notification of specialty pharmacy medical step therapy updates

Please note, this communication applies to Healthy Blue + MedicareSM (HMO-POS D-SNP) offered by Blue Cross and Blue Shield of North Carolina (Blue Cross NC).

This is a courtesy notice as there is no change to current status of Eylea HD in the Medical Step Therapy Program. The step criteria for anti-vascular endothelial growth factor (VEGF) inhibitors found in *Clinical Criteria* document CC-0072 will formally list Eylea HD as a preferred product.

Clinical UM Guidelines are publicly available on the provider website. Visit the [Clinical Criteria page](#) to search for specific criteria.

<i>Clinical UM Guidelines</i>	Preferred drug(s)	Nonpreferred drug(s)
CC-0072	Avastin Byooviz Cimerli Eylea Eylea HD Lucentis Vabysmo	Beovu Macugen

Through genuine collaboration, we can simplify access to care and help you deliver high-quality, equitable healthcare.

<https://www.bluecrossnc.com/providers/networks-programs/blue-medicare/healthy-blue-medicare>

Blue Cross and Blue Shield of North Carolina Senior Health, DBA Blue Cross and Blue Shield of North Carolina, is an HMO-POS D-SNP plan with a Medicare contract and a NC State Medicaid Agency Contract (SMAC). Enrollment in Blue Cross and Blue Shield of North Carolina Senior Health depends upon contract renewal.

®, SM are marks of the Blue Cross Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross Blue Shield Association.
NCBCBS-CR-046823-23-CPN45766 January 2024